A preclinical investigation into the potential associations of geraniin with ulcerative colitis alleviation through integrated multi-omics and in vivo analysis - Scorecard - MDSpire
Advertisement
A preclinical investigation into the potential associations of geraniin with ulcerative colitis alleviation through integrated multi-omics and in vivo analysis
Clinical Scorecard: Exploring the Potential Role of Geraniin in Mitigating Ulcerative Colitis: A Preclinical Study Utilizing Multi-Omics and In Vivo Approaches
At a Glance
Category
Detail
Condition
Ulcerative Colitis
Key Mechanisms
Modulation of inflammatory pathways including IL-17, TNF, and CXCR chemokine signaling.
Target Population
Patients with Ulcerative Colitis, particularly younger individuals aged 15-25.
Care Setting
Preclinical research using murine models.
Key Highlights
Geraniin targets 27 genes associated with UC.
In vivo studies show reduced DAI scores and enhanced colon length with geraniin treatment.
Geraniin treatment correlates with decreased M1 macrophage markers and increased M2 macrophage markers.
Geraniin modulates inflammatory responses by affecting NOS2 and PPARG expression.
Guideline-Based Recommendations
Diagnosis
Utilize transcriptomic and single-cell data for understanding UC pathology.
Management
Consider geraniin as a potential therapeutic alternative for UC.
Monitoring & Follow-up
Evaluate DAI scores and histopathological changes in UC patients.
Risks
Monitor for potential recurrence and adverse effects associated with current pharmacological treatments.
Patient & Prescribing Data
Individuals diagnosed with Ulcerative Colitis.
Geraniin shows promise as a natural anti-inflammatory agent with low toxicity.
Clinical Best Practices
Incorporate multi-omics approaches in UC research.
Focus on the modulation of immune cell phenotypes in treatment strategies.
